SLC5A2 and metabolic syndrome: In our view, this represents the major strength of the proposed multidisciplinary integrated approach, in order to address both hesitancy/inertia of nephrologists to prescribe SGLT-2 inhibitors and the suboptimal management of kidney disease by diabetologists, particularly in handling hypertension, hyperuricemia, and dyslipidemia.